PARENTS of overweight kids have welcomed the news that a major study has found that fat jabs are safe for children. But ...

Novo Nordisk's lawsuit seeks a permanent injunction forcing Eli Lilly to pull the ads, as well as a corrective ad campaign.

As GLP-1 drug use surges nationwide, overall spending could soon drive up healthcare costs for everyone, according to a new study.

A new study reveals how next generation GIPR drugs act on the brainstem and hypothalamus to boost weight loss.

Retatrutide just took a major step in its journey toward FDA approval. Eli Lilly, the company that makes retatrutide, announced the topline results from its TRIUMPH clinical trial program. Retatrutide ...

Cambridge scientists have solved the mystery of why both stimulating and blocking a particular 'switch' in the brain can help ...

Novo Nordisk, through its drugs Ozempic and Wegovy, and Eli Lilly are competing to control the nearly $80 billion weight-loss drug market. How much weight a drug helps patients lose is a key ...

Sister’s rigid relationship with food and her resistance to talking about it worry the letter writer.

Movement, balance, posture, and strength “can all be altered if you have too much muscle loss,” Ravussin said. Indeed, loss of lean mass due to GLP-1 use could lead to osteoporosis, frailty, and ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak ...